Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Breast cancer stem cell regulation

SABCS 2008

10 - 14 Dec 2008

Published: 12 Jan 2009

Views: 19026

Rating:

Save

Professor Max Wicha, Director, University of Michigan Comprehensive Cancer Center

Understanding breast cancer stem cells, how breast cancer tumours recruit stem cells from the bone, and inhibiting receptor CXCR1 using an anti-inflamatory drug to knock out cancer stem cells- a whole new approach

Related Videos

Endocrine therapy plus trastuzumab and pertuzumab shows excellent survival outcomes in HR and HER2 positive early BC

Dr Oleg Gluz - Evangeliches Krankenhaus Bethesda Klinik, Mönchengladbach, Germany

Endocrine therapy plus trastuzumab and pertuzumab shows excellent survival outcomes in HR and HER2 positive early BC ( Dr Oleg Gluz - Evangeliches Krankenhaus Bethesda Klinik, Mönchengladbach, Germany )

Trastuzumab deruxtecan significantly improves PFS In breast cancer patients previously treated with endocrine therapy

Prof Giuseppe Curigliano - European Institute of Oncology, Milan, Italy

Trastuzumab deruxtecan significantly improves PFS In breast cancer patients previously treated with endocrine therapy ( Prof Giuseppe Curigliano - European Institute of Oncology, Milan, Italy )

Adjuvant avelumab versus control does not significantly improve DFS but does improve OS in high-risk TNBC patients

Prof Pier Conte - University of Padova, Padova, Italy

Adjuvant avelumab versus control does not significantly improve DFS but does improve OS in high-risk TNBC patients ( Prof Pier Conte - University of Padova, Padova, Italy )

HER2DX assay and survival outcomes: An individual-patient level meta-analysis of 2,031 patients with HER2-positive BC

Dr Guillermo Villacampa - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

HER2DX assay and survival outcomes: An individual-patient level meta-analysis of 2,031 patients with HER2-positive BC ( Dr Guillermo Villacampa - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain )

OncoAlert round up July 28th to August 3rd, 2023

Dr Gil Morgan - Executive Director, OncoAlert

OncoAlert round up July 28th to August 3rd, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )

Updates on HR-positive HER2-negative breast cancer

Dr Mariana Chavez - MD Anderson Cancer Center, Houston, USA

Updates on HR-positive HER2-negative breast cancer ( Dr Mariana Chavez - MD Anderson Cancer Center, Houston, USA )

ASCO 2023: Highlights and analysis

Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada

ASCO 2023: Highlights and analysis ( Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada )

Nine-weeks trastuzumab still effective compared with one year trastuzumab for early-stage HER2 positive breast cancer

Prof Pierfranco Conte - Istituto Oncologico Veneto, Padova, Italy

Nine-weeks trastuzumab still effective compared with one year trastuzumab for early-stage HER2 positive breast cancer ( Prof Pierfranco Conte - Istituto Oncologico Veneto, Padova, Italy )

Breast cancer in elderly patients: a clinicopathological review of a Nigerian database

Dr Funmilola Wuraola - Obafemi Awolowo University Teaching Hospital, Ilé-Ifẹ̀, Nigeria

Breast cancer in elderly patients: a clinicopathological review of a Nigerian database ( Dr Funmilola Wuraola - Obafemi Awolowo University Teaching Hospital, Ilé-Ifẹ̀, Nigeria )

More from ecancer